Maini R N, Elliott M J, Brennan F M, Feldmann M
Kennedy Institute of Rheumatology, London, UK.
Clin Exp Immunol. 1995 Aug;101(2):207-12. doi: 10.1111/j.1365-2249.1995.tb08340.x.
The biological properties of TNF-alpha make it a candidate therapeutic target in RA. Our studies have demonstrated that TNF-alpha and its receptors are up-regulated and co-expressed in the synovium and cartilage-pannus junction of RA joints. Neutralizing TNF-alpha antibodies reduce the production of the many pro-inflammatory cytokines, including IL-1 and granulocyte-macrophage colony-stimulating factor (GM-CSF), produced by mononuclear cells from RA in culture. When injected into DBA/1 mice with collagen-induced arthritis and TNF-alpha transgenic mice with arthritis, anti-TNF MoAbs decrease inflammatory damage of joints. Clinical trials employing cA2, a chimaeric anti-TNF-alpha MoAb, in open-label and randomized placebo-controlled studies have demonstrated a dose-dependent efficacy with impressive improvement in disease activity and acute-phase responses lasting several weeks. We conclude that TNF-alpha is a critical mediator of inflammation in RA, and is an important therapeutic target in this disease.
肿瘤坏死因子-α(TNF-α)的生物学特性使其成为类风湿关节炎(RA)的一个候选治疗靶点。我们的研究表明,TNF-α及其受体在RA关节的滑膜和软骨-血管翳交界处上调并共同表达。中和TNF-α抗体可减少培养的RA单核细胞产生的多种促炎细胞因子,包括白细胞介素-1(IL-1)和粒细胞-巨噬细胞集落刺激因子(GM-CSF)。当注射到胶原诱导性关节炎的DBA/1小鼠和患有关节炎的TNF-α转基因小鼠中时,抗TNF单克隆抗体可减少关节的炎症损伤。在开放标签和随机安慰剂对照研究中使用嵌合抗TNF-α单克隆抗体cA2的临床试验表明,其具有剂量依赖性疗效,疾病活动和急性期反应有显著改善,且持续数周。我们得出结论,TNF-α是RA炎症的关键介质,也是该疾病的重要治疗靶点。